DiaMedica amends ReMEDy2 stroke trial protocol; cash $56.2M with runway to 2026

DiaMedica Therapeutics Inc.

FDA 30-day review of protocol amendments passed without comment; changes focus on moderate anterior circulation strokes (NIHSS 5-15).
Initial US clinical site activations expected in Nov-Dec 2023; full enrollment for interim analysis targeted by 2024.
Cash and investments $56.2M as of Sep 30, 2023, up from $33.5M at Dec 31, 2022; cash runway into 2026.
Q3 2023 R&D expenses $3.3M (vs $1.6M Q3 2022); G&A $1.9M (vs $1.5M); net cash used in operations $14.9M for nine months (vs $8.7M prior).

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

DiaMedica Therapeutics Inc. reported financial results for three and nine-month periods ended September 30, 2023.

Period: three and nine-month periods ended September 30, 2023
Result: reported results

Exact text from the filing

On November 13, 2023, DiaMedica Therapeutics Inc. (the “Company”) announced its consolidated financial results for the three and nine-month periods ended September 30, 2023. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and the information set forth therein is incorporated herein by reference and constitutes a part of Item 2.02 of this report.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

DiaMedica Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-031669

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.